Thursday

Relevance of Mitochondrial Dysfunction in the Experimental Fibromyalgia Model.


Fibromyalgia (FM) is one of the most common musculoskeletal pain conditions. 
Although the cause of FM is still unknown, mitochondrial dysfunction and the overproduction of reactive oxygen intermediates (ROI) are common characteristics in its development. ROI's play diverse roles in inflammation
Mitochondria are the “energy factory” of our body. Mitochondrial diseases are long-term, genetic, often inherited disorders that occur when mitochondria fail to produce enough energy for the body to function properly. CLEVELAND CLINIC 
The reserpine experimental model can induce FM-related symptoms in rodents by depleting biogenic amines. However, it is unclear whether reserpine causes other processes associated with the disease characteristics of FM. 
So far, no one has investigated the relevance of mitochondrial dysfunction in the reserpine-induced experimental FM model using protection- and insult-based mitochondrial modulators. 

What are mitochondria?

Mitochondria are the “energy factory” of our body. Several thousand mitochondria are in nearly every cell in the body. Their job is to process oxygen and convert substances from the foods we eat into energy. Mitochondria produce 90% of the energy our body needs to function.
What are mitochondria?
METHODS
Reserpine (1 mg/kg) was subcutaneously injected once daily for three consecutive days in male Swiss mice. We carried out analyses of reserpine-induced FM-related symptoms, and their modulation by using mitochondrial insult on ATP synthesis (oligomycin; 1 mg/kg, intraperitoneally) or mitochondrial protection (coenzyme Q10; 150 mg/kg/5 days, orally). We also evaluated the effect of reserpine on mitochondrial function using high-resolution respirometry and oxidative status. 
RESULTS
Reserpine caused:
  •  nociception, 
  • loss in muscle strength, and 
  • anxiety- and depressive-like behaviours 

These symptoms were consistent with the clinical symptoms of FM. They did not induce body weight and temperature alterations or motor impairment.
Reserpine-induced FM-related symptoms were increased by oligomycin and reduced by coenzyme Q10 treatment
Reserpine caused mitochondrial dysfunction by negatively modulating the electron transport system and mitochondrial respiration (ATP synthesis) mainly in oxidative muscles and the spinal cord. 
These results support the role of mitochondria in mediating oxidative stress and FM symptoms in this model. In this way, reserpine-inducing mitochondrial dysfunction and increased production of ROI contribute to the development and maintenance of nociceptive, fatigue, and depressive-like behaviours.

References:

FIBRO FILES: Fibro in the media this week.

Fibromyalgia in the media this week.

Chronic Pain May Be Effectively Treated Using Placebo Effect: 60 patients with osteoarthritis and 79 patients with fibromyalgia as well as 98 healthy individuals were given an inert cream to be applied on their forehand. Pavankumar Kamat, 
July 16, 2020, Medscape.


Cancer and Fibromyalgia: Addressing the Needs of Patients Despite Limited Research. Mary Hanley, LMSW CancerCare, July 15, 2020, Oncology Nurse Advisor. Having either cancer or fibromyalgia is a challenge that millions of Americans face every year. But how do those with comorbid cancer and fibromyalgia fare? Addressing comorbidity between cancer and fibromyalgia is an emerging, but still lacking, area of research. 

Development for Bedtime Treatment of Fibromyalgia. Tonix Pharmaceuticals. Tonix is developing TNX-102 SL as a potential treatment for the symptoms of Fibromyalgia. It is currently in Phase 3 clinical development. TNX-102 SL targets mechanisms which are associated with disturbed sleep. It is believed that increasing sleep quality in fibromyalgia may facilitate the body's adaptive ability to modulate the perception of pain.

Patients with fibromyalgia, OA, RA at increased risk for self-harm: according to findings published in Arthritis Care & Research. Carrie Beach, July 08, 2020, Healio. 

“Our interest lies in examining and comparing the risk of self-harm in specific rheumatological conditions (ankylosing spondylitis, fibromyalgia, osteoarthritis and rheumatoid arthritis),” James A. Prior, BSc, MSc, PhD, of Keele University, in Staffordshire, UK.